Lansdall CJ, McDougall F, Butler LM, Delmar P, Pross N, Qin S, McLeod L, Zhou X, Kerchner GA, Doody RS. Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease. J Prev Alzheimers Dis. 2023;10(1):9-18. doi: 10.14283/jpad.2022.102
Romano (DeMuro) C, Novak G, Choi J, Qin S, Henley D, Donohue M, Romano G, Raman R, Amariglio R, Aisen P, Sperling R. Assessing clinically meaningful functional outcomes in preclinical alzheimer's disease. Poster presented at the 15th Conference Clinical Trials Alzheimer's Disease 2022; November 29, 2022. San Francisco, CA. [abstract] J Prev Alzheimers Dis. 2022 Dec 3; 9(Supplement 1):S186-7.
Bell CF, Lau M, Lee M, Poulos C. Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE. Clin Rheumatol. 2021 Feb;40(2):581-90. doi: 10.1007/s10067-020-05226-w
Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the 2020 Muscle Study Group (MSG) Annual Virtual Meeting; September 25, 2020. [abstract] RRNMF Neu J. 2020 Sep; 1(4):61.
Laramee P, Bell M, Irving A, Brodtkorb TH. The cost-effectiveness of the integration of nalmefene within the UK healthcare system treatment pathway for alcohol dependence. Alcohol Alcohol. 2016 May;51(3):283-90. doi: 10.1093/alcalc/agv140